L. reuteri for Depression: The Multi-Strain Catch

Lactobacillus reuteri alone does not have convincing evidence as a depression supplement. A 2025 meta-analysis found that the apparent benefit of L. reuteri-containing treatments came from multi-strain formulas, not single-strain products. That distinction matters if you are considering a bottle marketed for mood.

Across 12 randomized controlled trials involving 1,258 participants, Cheng et al.'s 2025 systematic review and meta-analysis found a statistically significant overall reduction in depressive symptoms with interventions containing L. reuteri: standardized mean difference (SMD) −0.44, 95% confidence interval (CI) −0.72 to −0.16. But the subgroup analysis changes the practical reading of that result. Single-strain L. reuteri did not significantly improve depressive symptoms. Multi-strain products containing L. reuteri produced an SMD of −0.56 (95% CI −0.97 to −0.15).

The meta-analysis is a useful first attempt to ask a more precise question than "Do probiotics help depression?" Its answer is not that one strain has earned antidepressant status. It is that certain mixtures containing that strain may reduce symptoms, while the available trials cannot tell us whether L. reuteri caused the benefit, helped other organisms work, or merely rode along in the capsule.

What the effect size does—and does not—say

An SMD expresses the difference between treatment and comparison groups in standard-deviation units when trials use different depression scales. The multi-strain estimate of −0.56 is compatible with a moderate average effect, but its CI is wide: it ranges from −0.97 to −0.15. That span allows for anything from a small benefit to a much larger one. Differences among trial populations, probiotic mixtures, treatment durations, and symptom scales likely contributed to that uncertainty.

The overall estimate, SMD −0.44 (95% CI −0.72 to −0.16), has the same problem. It is statistically significant, but the precision is limited. With only 12 trials split into formulation subgroups, neither the positive multi-strain result nor the single-strain null result settles the question beyond dispute. The null result could mean that single-strain L. reuteri has no material antidepressant effect, or that the subgroup had too few participants to detect one. Still, it is the evidence-based result available to shoppers today.

The review found larger signals among participants younger than 60 years (SMD −0.52), female participants (SMD −0.45), and "other clinical populations" (SMD −0.59), a category likely to include subthreshold or secondary depressive presentations. These are subgroup findings, not rules for selecting a supplement. They may reflect biology, differences in baseline symptom burden, chance, or characteristics of the trials that happened to enroll those groups.

This is a formulation result, not proof of strain synergy

Every favorable trial in Cheng and colleagues' review used a mixed formulation containing L. reuteri alongside other Lactobacillus and Bifidobacterium species. None used a factorial design that compared L. reuteri alone, companion strains alone, and their combination in otherwise matched groups. Without that design, no one can assign credit to a single organism.

One example is Lee et al.'s 2021 randomized, double-blind, placebo-controlled trial of NVP-1704 in healthy adults. Participants took the multi-strain product, which included L. reuteri plus other Lactobacillus and Bifidobacterium strains, or placebo for eight weeks. It is relevant because it tests the class of intervention that generated the positive subgroup signal. It cannot establish that L. reuteri itself accounted for any mental-health outcome.

A consortium explanation is biologically plausible. Reviews of the gut-brain axis describe immune signaling, neuroendocrine pathways, and vagal communication as possible routes through which microbial interventions could affect mood. Kaur et al.'s 2025 review argues that ecosystem-level microbial interactions may matter in depression. Plausibility is not attribution. A mechanism that could explain a multi-strain effect does not identify the organism doing the work.

Human biomarker research remains preliminary. Dacaya et al.'s 2025 secondary analysis studied adults with subthreshold depression who received a multi-species probiotic and measured plasma GABA and serotonin. Those are mechanistic clues, not patient-centered proof that a particular strain changes brain neurotransmission or treats depression.

How it compares with the broader probiotic literature

The multi-strain estimate sits within, or modestly above, the range reported in broader reviews of probiotics for depression. Lin et al.'s 2023 meta-analysis and El Dib et al.'s 2021 review reported effects in roughly the −0.3 to −0.5 SMD range for probiotics versus placebo. That consistency supports the possibility that some probiotic interventions can reduce depressive symptoms. It also weakens claims that L. reuteri has shown a unique advantage: −0.56 does not establish that the strain improves on other probiotic mixtures.

A 2024 network meta-analysis by Zhao et al. compared probiotics and antidepressants for adults with major depressive disorder and found broadly overlapping confidence intervals. This makes the probiotic signal clinically interesting, but it does not show that a probiotic can replace an antidepressant. Network comparisons are indirect; probiotic and antidepressant trials can differ in diagnostic thresholds, placebo response, blinding, and outcome measures. A randomized head-to-head trial would answer a different and much more useful question.

There is also some reassurance on tolerability in Cheng and colleagues' review. Acceptability did not differ meaningfully between L. reuteri-containing interventions and controls (odds ratio 1.04, 95% CI 0.75–1.45). This is not an efficacy result, and it does not eliminate individual risks or product-quality concerns, but the pooled trials did not show a clear acceptability penalty.

Population matters more than supplement marketing admits

People with diagnosed depression, subthreshold symptoms, and no meaningful symptoms should not expect the same result. A 2026 meta-analysis of healthy working adults found attenuated effects of probiotic intake on mental health compared with clinical populations. That is especially relevant to prevention-minded users who feel generally well and want a mood upgrade. When baseline symptoms leave little room to improve, a trial result from symptomatic participants may shrink or disappear.

Age also limits broad claims. A 2024 systematic review in children and adolescents found that probiotics largely failed to improve depression symptoms in that population. The finding does not prove that adolescents cannot benefit from any future formulation, but it blocks the easy move from adult data to younger people.

Inflammation may be another source of variation. A 2025 double-blind, placebo-controlled trial tested add-on probiotics in people with inflammatory depression, raising the possibility that response depends partly on inflammatory phenotype. This could help explain why aggregate results vary, but current evidence does not show that an inflammation test can identify who should take L. reuteri.

The practical verdict

Do not buy single-strain L. reuteri for depression because a label implies that the strain itself has an antidepressant effect. Cheng and colleagues' central finding points the other way: single-strain L. reuteri did not significantly improve depressive symptoms.

If you choose to try a probiotic as an adjunct, the evidence is more consistent with a multi-strain formula that includes L. reuteri, especially for adults with actual depressive symptoms rather than healthy people seeking a subtle lift. But no current trial set identifies the necessary companion strains, dose, ratio, or duration. Commercial products such as BioGaia or strains such as ATCC PTA 6475 cannot be assumed to reproduce the mixtures studied.

Current evidence supports a formulation class, not a single-strain mood claim. For depression, probiotics are an experimental adjunct—not a substitute for assessment, psychotherapy, medication when indicated, or urgent care for suicidal thoughts.

The next informative trial would compare L. reuteri alone, specified companion strains alone, and their combination in the same population using the same depression endpoint. Until that study arrives, the honest conclusion is narrow: mixed probiotics containing L. reuteri show a possible benefit; L. reuteri alone has not.